ScienceOpen:
research and publishing network
For Publishers
Discovery
Metadata
Peer review
Hosting
Publishing
For Researchers
Join
Publish
Review
Collect
My ScienceOpen
Sign in
Register
Dashboard
Blog
About
Search
Advanced search
My ScienceOpen
Sign in
Register
Dashboard
Search
Search
Advanced search
For Publishers
Discovery
Metadata
Peer review
Hosting
Publishing
For Researchers
Join
Publish
Review
Collect
Blog
About
10
views
0
references
Top references
cited by
41
Cite as...
0 reviews
Review
0
comments
Comment
0
recommends
+1
Recommend
0
collections
Add to
0
shares
Share
Twitter
Sina Weibo
Facebook
Email
1,458
similar
All similar
Record
: found
Abstract
: not found
Article
: not found
Low-density lipoprotein, non-high-density lipoprotein, and apolipoprotein B as targets of lipid-lowering therapy.
Author(s):
Scott M. Grundy
Publication date:
2002-11-12
Journal:
Circulation
Keywords:
Apolipoproteins B
,
blood
,
Cholesterol
,
Cholesterol, HDL
,
Coronary Artery Disease
,
epidemiology
,
Coronary Disease
,
drug therapy
,
Drug Delivery Systems
,
Humans
,
Hypolipidemic Agents
,
therapeutic use
,
Lipoproteins
,
Lipoproteins, LDL
,
Prognosis
,
Risk Factors
Read this article at
ScienceOpen
PubMed
Review
Review article
Invite someone to review
Bookmark
Cite as...
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Related collections
Drug_transporters
Author and article information
Journal
PubMed ID::
12427645
ScienceOpen disciplines:
Chemistry
Keywords:
Apolipoproteins B
,
blood
,
Cholesterol
,
Cholesterol, HDL
,
Coronary Artery Disease
,
epidemiology
,
Coronary Disease
,
drug therapy
,
Drug Delivery Systems
,
Humans
,
Hypolipidemic Agents
,
therapeutic use
,
Lipoproteins
,
Lipoproteins, LDL
,
Prognosis
,
Risk Factors
Data availability:
ScienceOpen disciplines:
Chemistry
Keywords:
Apolipoproteins B
,
blood
,
Cholesterol
,
Cholesterol, HDL
,
Coronary Artery Disease
,
epidemiology
,
Coronary Disease
,
drug therapy
,
Drug Delivery Systems
,
Humans
,
Hypolipidemic Agents
,
therapeutic use
,
Lipoproteins
,
Lipoproteins, LDL
,
Prognosis
,
Risk Factors
Comments
Comment on this article
Sign in to comment
Similar content
1,458
siRNA-induced liver ApoB knockdown lowers serum LDL-cholesterol in a mouse model with human-like serum lipids.
Authors:
José Castro
,
Chen Chen
,
Liwen Zhang
…
IQ, Educational Attainment, Memory and Plasma Lipids: Associations with Apolipoprotein E Genotype in 5995 Children
Authors:
Amy E Taylor
,
Philip A.I. Guthrie
,
George Davey Smith
…
Alirocumab efficiently reduces Lp(a) levels by lowering apolipoprotein (a) [apo(a)] production rate in non-human primates (NHP)
Authors:
Thi-Thu-Trang Tran
,
Mikaël Croyal
,
Rose-Hélène Blanchard
…
See all similar
Cited by
38
Atherosclerosis and Alzheimer - diseases with a common cause? Inflammation, oxysterols, vasculature
Authors:
Richard Lathe
,
Alexandra Sapronova
,
Yuri Kotelevtsev
Non-HDL cholesterol and apolipoprotein B predict cardiovascular disease events among men with type 2 diabetes.
Authors:
R. Jiang
,
M Schulze
,
T. Li
…
Substitution of red meat with legumes in the therapeutic lifestyle change diet based on dietary advice improves cardiometabolic risk factors in overweight type 2 diabetes patients: a cross-over randomized clinical trial.
Authors:
S Hosseinpour-Niazi
,
P Mirmiran
,
M Hedayati
…
See all cited by